| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,039 |
7,269 |
$1.54M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,016 |
9,039 |
$1.42M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,663 |
1,797 |
$491K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,642 |
2,022 |
$182K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,340 |
3,283 |
$177K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,127 |
1,738 |
$144K |
| 70450 |
Computed tomography, head or brain; without contrast material |
188 |
156 |
$103K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,046 |
745 |
$87K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,418 |
1,885 |
$75K |
| 80053 |
Comprehensive metabolic panel |
10,605 |
8,370 |
$69K |
| 71046 |
Radiologic examination, chest; 2 views |
822 |
666 |
$66K |
| 71045 |
Radiologic examination, chest; single view |
980 |
744 |
$63K |
| J3490 |
Unclassified drugs |
5,232 |
2,865 |
$59K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
454 |
312 |
$55K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,461 |
7,653 |
$47K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
405 |
354 |
$42K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
231 |
167 |
$28K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
31 |
27 |
$25K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
359 |
329 |
$25K |
| 36415 |
Collection of venous blood by venipuncture |
8,761 |
6,179 |
$15K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
2,356 |
1,317 |
$14K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
288 |
209 |
$13K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
155 |
112 |
$12K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
518 |
448 |
$12K |
| 87400 |
|
984 |
422 |
$10K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
598 |
510 |
$10K |
| 80061 |
Lipid panel |
858 |
817 |
$10K |
| 87430 |
|
752 |
619 |
$9K |
| 83735 |
|
2,321 |
1,787 |
$8K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
147 |
100 |
$8K |
| 84443 |
Thyroid stimulating hormone (TSH) |
531 |
493 |
$7K |
| 94664 |
|
170 |
141 |
$7K |
| 80050 |
General health panel |
191 |
149 |
$7K |
| 84484 |
|
1,113 |
792 |
$6K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
66 |
60 |
$6K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
205 |
50 |
$6K |
| 81001 |
|
2,998 |
2,343 |
$5K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
88 |
74 |
$5K |
| 81025 |
|
770 |
590 |
$5K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
100 |
85 |
$4K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
662 |
545 |
$4K |
| 82553 |
|
911 |
557 |
$4K |
| 82550 |
|
853 |
615 |
$3K |
| 87449 |
|
237 |
188 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
159 |
135 |
$3K |
| 80305 |
|
325 |
229 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
184 |
139 |
$2K |
| 84481 |
|
293 |
158 |
$2K |
| 83880 |
|
139 |
98 |
$2K |
| 74018 |
|
15 |
15 |
$2K |
| 82607 |
|
157 |
143 |
$2K |
| 84439 |
|
329 |
191 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
24 |
24 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
24 |
24 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
17 |
12 |
$874.10 |
| 85027 |
|
121 |
110 |
$627.79 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
40 |
15 |
$588.59 |
| 87040 |
|
125 |
66 |
$581.48 |
| 83690 |
|
107 |
90 |
$509.90 |
| 82150 |
|
67 |
53 |
$278.64 |
| 84480 |
|
33 |
33 |
$244.44 |
| 81003 |
|
214 |
132 |
$228.75 |
| J7510 |
Prednisolone oral, per 5 mg |
14 |
14 |
$122.94 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
48 |
42 |
$108.44 |
| 83605 |
|
13 |
13 |
$92.33 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
12 |
12 |
$84.60 |
| 82570 |
|
13 |
13 |
$59.42 |
| 85007 |
|
17 |
12 |
$27.13 |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
803 |
72 |
$0.00 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
14 |
14 |
$0.00 |